HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) All Versions of this Article: 0091270006298360v1 47/5/553    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (5) Citing Articles via Google Scholar Google Scholar Articles by Mascelli, M. A. Articles by Abernethy, D. Search for Related Content PubMed PubMed Citation Articles by Mascelli, M. A. Articles by Abernethy, D. Social Bookmarking                         What's this?

Molecular, Biologic, and Pharmacokinetic Properties of Monoclonal Antibodies: Impact of These Parameters on Early Clinical Development

From Centocor R and D, Malvern, Pennsylvania; PK/PD, Inc, Philadelphia, Pennsylvania; and National Institute on Aging, National Institutes of Health, Baltimore, Maryland.

Currently, 14 intact, unconjugated, monoclonal antibodies (Mabs) are approved for therapeutic use in the United States, and more than 100 Mabs are presently undergoing clinical development or regulatory review. Mabs are large molecular weight glycoproteins that embody structural, biochemical, and pharmacologic properties distinct from other biologics or chemically synthesized compounds. Early therapeutic Mabs were murine proteins, and clinical testing of these agents revealed serious immune-mediated toxicities. The side effect profile of murine Mab therapeutic agents restricted the clinical development of these agents to indications with high morbidity and/or mortality (ie, oncology, graft vs host rejection). Advances in genetic engineering and protein expression technologies resulted in the development of Mabs composed either predominately (ie, mouse/human chimeric, "humanized") or completely (ie, "fully human" Mabs) of the human amino acid sequence. The production of chimeric, humanized, and fully human Mabs significantly reduced the immune-mediated toxicities and expanded the utility for these agents in numerous therapeutic areas, particularly in chronic disorders requiring either long-term administration (ie, rheumatoid arthritis) or treatment upon the flare up of disease (Crohn's disease, psoriasis). This review provides an overview of the molecular, biochemical, and pharmacokinetic properties and clinical development history of Mabs and details how these factors currently affect the scope and design of early clinical development strategies for these drug candidates. Emphasis is placed on the criteria for selecting appropriate subject populations for phase I testing of Mabs.

Key Words: Monoclonal antibodies • first in human • phase I clinical trials • pharmacokinetics • pharmacodynamics

Address for reprints: Address for correspondence: Mary Ann Mascelli, Centocor R and D, 200 Great Valley Parkway, Malvern, PA 19355.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M.K. Mundae and A.J.K. Ostor The long road of biopharmaceutical drug development: from inception to marketing QJM, October 21, 2009; (2009) hcp145v1. [Abstract] [Full Text] [PDF]

				Z. Xu, T. Vu, H. Lee, C. Hu, J. Ling, H. Yan, D. Baker, A. Beutler, C. Pendley, C. Wagner, et al. Population Pharmacokinetics of Golimumab, an Anti-Tumor Necrosis Factor-{alpha} Human Monoclonal Antibody, in Patients With Psoriatic Arthritis J. Clin. Pharmacol., September 1, 2009; 49(9): 1056 - 1070. [Abstract] [Full Text] [PDF]

				Y. Zhu, C. Hu, M. Lu, S. Liao, J. C. Marini, J. Yohrling, N. Yeilding, H. M. Davis, and H. Zhou Population Pharmacokinetic Modeling of Ustekinumab, a Human Monoclonal Antibody Targeting IL-12/23p40, in Patients With Moderate to Severe Plaque Psoriasis J. Clin. Pharmacol., February 1, 2009; 49(2): 162 - 175. [Abstract] [Full Text] [PDF]

				Z. Xu, K. Seitz, A. Fasanmade, J. Ford, P. Williamson, W. Xu, H. M. Davis, and H. Zhou Population Pharmacokinetics of Infliximab in Patients With Ankylosing Spondylitis J. Clin. Pharmacol., June 1, 2008; 48(6): 681 - 695. [Abstract] [Full Text] [PDF]